O	0	1	A
O	2	13	prospective
O	14	24	randomized
O	25	35	controlled
O	36	41	trial
O	42	44	of
B-intervention	45	54	hydrating
I-intervention	55	59	nail
I-intervention	60	68	solution
O	69	72	for
O	73	83	prevention
O	84	86	or
O	87	96	treatment
O	97	99	of
B-condition	100	111	onycholysis
O	112	114	in
O	115	121	breast
O	122	128	cancer
O	129	137	patients
O	138	141	who
O	142	150	received
O	151	162	neoadjuvant
O	162	163	/
O	163	171	adjuvant
O	172	181	docetaxel
O	182	194	chemotherapy
O	194	195	.

O	196	207	Onycholysis
O	208	211	and
O	212	217	other
O	218	222	nail
O	223	233	toxicities
O	234	239	occur
O	240	242	in
O	243	256	approximately
O	257	259	20
O	259	260	-
O	260	262	30
O	262	263	%
O	264	266	of
O	267	273	breast
O	274	280	cancer
O	281	282	(
O	282	284	BC
O	284	285	)
O	286	294	patients
O	295	304	receiving
O	305	314	docetaxel
O	315	327	chemotherapy
O	327	328	.

O	329	340	Onycholysis
O	341	343	is
O	344	349	often
O	350	360	associated
O	361	365	with
O	366	373	painful
O	374	384	paronychia
O	384	385	,
O	386	396	decreasing
O	397	405	patients
O	405	406	'
O	407	414	quality
O	415	417	of
O	418	422	life
O	422	423	.

O	424	426	In
O	427	431	this
O	432	437	study
O	437	438	,
O	439	441	we
O	442	447	aimed
O	448	450	to
O	451	459	evaluate
O	460	463	the
O	464	472	efficacy
O	473	475	of
O	476	485	hydrating
O	486	490	nail
O	491	499	solution
O	500	501	(
O	501	504	HNS
O	504	505	)
O	506	507	(
O	507	514	EVONAIL
O	514	515	Â®
O	516	524	solution
O	524	525	,
O	526	531	Evaux
O	532	544	Laboratories
O	544	545	,
O	546	552	France
O	552	553	)
O	554	557	for
O	558	561	the
O	562	572	prevention
O	573	576	and
O	577	586	treatment
O	587	589	of
O	590	599	docetaxel
O	599	600	-
O	600	607	induced
O	608	619	onycholysis
O	620	623	and
O	624	628	nail
O	629	639	toxicities
O	639	640	.

O	641	645	This
O	646	651	study
O	652	655	was
O	656	657	a
O	658	669	prospective
O	669	670	,
O	671	681	randomized
O	681	682	,
O	683	693	controlled
O	694	699	study
O	700	702	of
O	703	706	HNS
O	707	710	for
O	711	714	the
O	715	725	prevention
O	726	728	or
O	729	738	treatment
O	739	741	of
O	742	753	onycholysis
O	754	756	in
B-eligibility	757	765	patients
I-eligibility	766	770	with
I-eligibility	771	780	docetaxel
I-eligibility	781	786	after
I-eligibility	787	798	doxorubicin
I-eligibility	799	803	plus
I-eligibility	804	820	cyclophosphamide
O	820	821	.

O	822	824	In
O	825	828	the
O	829	841	experimental
O	842	845	arm
O	845	846	,
O	847	855	patients
O	856	863	painted
O	864	867	HNS
O	868	870	on
O	871	876	nails
O	877	880	and
O	881	891	periungual
O	892	897	areas
O	898	902	once
O	903	904	a
O	905	908	day
O	909	913	till
O	914	924	developing
O	925	936	onycholysis
O	937	942	grade
O	943	944	2
O	944	945	.

O	946	951	After
O	952	957	grade
O	958	959	2
O	960	971	onycholysis
O	972	983	development
O	983	984	,
O	985	993	patients
O	994	1001	applied
O	1002	1005	HNS
O	1006	1011	twice
O	1012	1013	a
O	1014	1017	day
O	1018	1028	regardless
O	1029	1031	of
O	1032	1041	treatment
O	1042	1045	arm
O	1045	1046	.

O	1047	1050	The
O	1051	1058	primary
O	1059	1068	endpoints
O	1069	1073	were
O	1074	1077	the
B-outcome-Measure	1078	1087	incidence
I-outcome-Measure	1088	1090	of
I-outcome-Measure	1091	1102	onycholysis
I-outcome-Measure	1103	1108	grade
I-outcome-Measure	1109	1110	2
O	1111	1114	and
B-outcome-Measure	1115	1123	recovery
I-outcome-Measure	1124	1128	rate
I-outcome-Measure	1129	1133	from
I-outcome-Measure	1134	1139	grade
I-outcome-Measure	1140	1141	2
I-outcome-Measure	1142	1153	onycholysis
O	1153	1154	.

O	1155	1159	From
O	1160	1166	August
O	1167	1171	2015
O	1172	1174	to
O	1175	1178	May
O	1179	1183	2016
O	1183	1184	,
B-total-participants	1185	1188	103
O	1189	1197	patients
O	1198	1202	were
O	1203	1211	enrolled
O	1212	1215	and
O	1216	1225	completed
O	1226	1230	this
O	1231	1236	study
O	1236	1237	.

O	1238	1240	Of
O	1241	1246	these
O	1246	1247	,
O	1248	1250	25
O	1251	1256	cases
O	1257	1259	of
B-outcome	1260	1265	grade
I-outcome	1266	1267	1
O	1268	1271	and
O	1272	1274	22
O	1275	1277	of
B-outcome	1278	1283	grade
I-outcome	1284	1285	2
I-outcome	1286	1297	onycholysis
O	1298	1302	were
O	1303	1311	observed
O	1311	1312	.

O	1313	1325	Prophylactic
O	1326	1337	application
O	1338	1340	of
O	1341	1344	HNS
O	1345	1353	resulted
O	1354	1356	in
O	1357	1358	a
O	1359	1372	statistically
O	1373	1384	significant
O	1385	1394	reduction
O	1395	1397	of
B-outcome	1398	1403	grade
I-outcome	1404	1405	2
I-outcome	1406	1417	onycholysis
O	1418	1426	compared
O	1427	1429	to
O	1430	1438	controls
O	1439	1440	(
O	1440	1441	P
O	1442	1443	=
O	1444	1445	0
O	1445	1446	.
O	1446	1449	001
O	1449	1450	)
O	1451	1454	and
O	1455	1458	all
O	1459	1464	grade
O	1465	1476	onycholysis
O	1477	1480	was
O	1481	1485	also
O	1486	1499	significantly
O	1500	1505	lower
O	1506	1508	in
O	1509	1512	the
O	1513	1525	experimental
O	1526	1529	arm
O	1530	1531	(
O	1531	1532	P
O	1533	1534	=
O	1535	1536	0
O	1536	1537	.
O	1537	1540	034
O	1540	1541	)
O	1541	1542	.

O	1543	1555	Multivariate
O	1556	1564	analysis
O	1565	1571	showed
O	1572	1576	that
O	1577	1580	HNS
O	1581	1590	decreased
B-outcome	1591	1596	grade
I-outcome	1597	1598	2
I-outcome	1599	1610	onycholysis
O	1611	1612	(
O	1612	1618	Hazard
O	1619	1624	ratio
O	1625	1626	(
O	1626	1628	HR
O	1628	1629	)
O	1630	1631	0
O	1631	1632	.
O	1632	1635	366
O	1635	1636	,
O	1637	1639	95
O	1639	1640	%
O	1641	1651	confidence
O	1652	1660	interval
O	1661	1662	(
O	1662	1664	CI
O	1664	1665	)
O	1666	1667	0
O	1667	1668	.
O	1668	1671	148
O	1671	1672	,
O	1673	1674	0
O	1674	1675	.
O	1675	1678	902
O	1678	1679	;
O	1680	1681	P
O	1682	1683	=
O	1684	1685	0
O	1685	1686	.
O	1686	1689	029
O	1689	1690	)
O	1691	1694	and
B-outcome	1695	1698	all
I-outcome	1699	1704	grade
I-outcome	1705	1716	onycholysis
O	1717	1718	(
O	1718	1720	HR
O	1721	1722	0
O	1722	1723	.
O	1723	1726	372
O	1726	1727	,
O	1728	1730	95
O	1730	1731	%
O	1732	1734	CI
O	1735	1736	0
O	1736	1737	.
O	1737	1740	201
O	1740	1741	-
O	1741	1742	0
O	1742	1743	.
O	1743	1746	687
O	1746	1747	,
O	1748	1749	P
O	1750	1751	=
O	1752	1753	0
O	1753	1754	.
O	1754	1757	002
O	1757	1758	)
O	1758	1759	.

O	1760	1769	Hydrating
O	1770	1774	nail
O	1775	1783	solution
O	1784	1797	significantly
O	1798	1805	reduced
O	1806	1809	the
O	1810	1819	incidence
O	1820	1822	of
O	1823	1832	docetaxel
O	1832	1833	-
O	1833	1840	induced
O	1841	1852	onycholysis
O	1853	1855	in
O	1856	1858	BC
O	1859	1867	patients
O	1868	1869	(
O	1869	1880	NCT02670603
O	1880	1881	)
O	1881	1882	.
